1. Home
  2. IKNA vs UPLD Comparison

IKNA vs UPLD Comparison

Compare IKNA & UPLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKNA
  • UPLD
  • Stock Information
  • Founded
  • IKNA 2016
  • UPLD 2010
  • Country
  • IKNA United States
  • UPLD United States
  • Employees
  • IKNA N/A
  • UPLD N/A
  • Industry
  • IKNA Biotechnology: Pharmaceutical Preparations
  • UPLD Computer Software: Prepackaged Software
  • Sector
  • IKNA Health Care
  • UPLD Technology
  • Exchange
  • IKNA Nasdaq
  • UPLD Nasdaq
  • Market Cap
  • IKNA 80.8M
  • UPLD 67.6M
  • IPO Year
  • IKNA 2021
  • UPLD 2014
  • Fundamental
  • Price
  • IKNA $1.71
  • UPLD $3.32
  • Analyst Decision
  • IKNA Buy
  • UPLD Hold
  • Analyst Count
  • IKNA 2
  • UPLD 3
  • Target Price
  • IKNA $3.00
  • UPLD $3.75
  • AVG Volume (30 Days)
  • IKNA 60.6K
  • UPLD 258.7K
  • Earning Date
  • IKNA 11-07-2024
  • UPLD 11-07-2024
  • Dividend Yield
  • IKNA N/A
  • UPLD N/A
  • EPS Growth
  • IKNA N/A
  • UPLD N/A
  • EPS
  • IKNA N/A
  • UPLD N/A
  • Revenue
  • IKNA $659,000.00
  • UPLD $278,945,000.00
  • Revenue This Year
  • IKNA N/A
  • UPLD N/A
  • Revenue Next Year
  • IKNA N/A
  • UPLD N/A
  • P/E Ratio
  • IKNA N/A
  • UPLD N/A
  • Revenue Growth
  • IKNA N/A
  • UPLD N/A
  • 52 Week Low
  • IKNA $1.22
  • UPLD $1.79
  • 52 Week High
  • IKNA $2.32
  • UPLD $5.28
  • Technical
  • Relative Strength Index (RSI)
  • IKNA 49.85
  • UPLD 66.95
  • Support Level
  • IKNA $1.71
  • UPLD $2.46
  • Resistance Level
  • IKNA $1.77
  • UPLD $3.86
  • Average True Range (ATR)
  • IKNA 0.05
  • UPLD 0.33
  • MACD
  • IKNA -0.00
  • UPLD 0.10
  • Stochastic Oscillator
  • IKNA 38.46
  • UPLD 67.72

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

About UPLD Upland Software Inc.

Upland Software Inc is a provider of cloud-based enterprise work management software. The company provides a family of cloud-based enterprise work management software applications for the information technology, process excellence, finance, professional services and marketing functions within organizations. It services customers ranging from corporations and Government agencies to small- and medium-sized businesses engaged in the field of financial services, retail, technology, manufacturing, education, consumer goods, media, and telecommunications, Government, food and beverage, healthcare and life sciences, chemicals and travel and hospitality. The products of the company are Altify, BA Insight, InGenius, Panviva, Qvidian, RightAnswers and others.

Share on Social Networks: